Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach

• Fujigaki, Seiji

• Nishiumi, Shin

• Kobayash, Takashi

• Suzuki, Makoto

• Iemoto, Takao

• Kojima, Takashi

• Ito, Yoshinori

• Daiko, Hiroyuki

• Kato, Ken

• Shouji, Hirokazu

• Honda, Kazufumi

• Azuma, Takeshi

• Yoshida, Masaru

Abstract

Aim: To identify the serum metabolomics signature that is correlated with the chemoradiosensitivity of esophageal squamous cell carcinoma (ESCC). Materials & methods: Untargeted and targeted metabolomics analysis of serum samples from 26 ESCC patients, which were collected before the neoadjuvant chemoradiotherapy, was performed. Results: On receiving the results of untargeted metabolomics analysis, we performed the targeted metabolomics analysis of the six metabolites (arabitol, betaine, glycine, L-serine, L-arginine and L-aspartate). The serum levels of the four metabolites (arabitol, glycine, L-serine and L-arginine) were significantly lower in the patients who achieved pathological complete response with neoadjuvant chemoradiotherapy compared with the patients who did not achieve pathological complete response (p = 0.0086, 0.0345, 0.0106 and 0.0373, respectively). Conclusion: The serum levels of metabolites might be useful for predicting the chemoradiosensitivity of ESCC patients.

Journal

• Biomarkers in Medicine

  Biomarkers in Medicine 12 (8), 827-840, 2018-08

  Future Medicine Ltd

Keywords

• 5-fluorouracil
• chemoradiosensitivity
• cisplatin
• esophageal squamous cell carcinoma
• metabolomics
• neoadjuvant therapy
• predictive biomarkers
• targeted metabolomics analysis

Details

• CRID: 1050856995322694784
• NII Article ID: 120006841463
• DOI: 10.2217/bmm-2017-0449
• ISSN: 17520371
• ISSN: 17520363
• HANDLE: 20.500.14094/90007061
• Web Site: https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2017-0449
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN